n n n ‘.concat(e.i18n.t(“search.voice.recognition_retry”),’n
Technology, authorized by the Massachusetts Institute of Technology (MIT), capable of placing DNA sequences of any length in any programmed genomic location
Potential to create curative mobile treatments and integrative genetic treatments.
Backed by leading biotech investors, Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others.
WATERTOWN, Mass. , Dec. 12, 2023 (GLOBE NEWSWIRE) — Tome Biosciences, Inc. , the programmable genomics integration company, has embarked to usher in a new era of genomic drugs on programmable genomic integration (PGI). insertion of any DNA sequence, of any size, into any programmed genomic location. The company has raised $213 million in Series A and B investments from investors: Andreessen Horowitz (a16z) Bio Health, ARCH Venture Partners, GV, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, Alexandria Venture Investments and others.
“PGI represents the maturation of editing technologies, breaking down existing barriers in genomic drug discovery,” said Rahul Kakkar, MD, president and chief executive officer. “PGI is revolutionary because, after all, we can reprogram the human genome with elegance and potency in the past was unimaginable. For patients with rare monogenic diseases, PGI enables potentially curative treatments with a single drug compatible with the disease, regardless of genetic heterogeneity, and for patients with more common diseases, PGI enables the creation of mobile treatments at the speed of biologics. discovery with a complexity that allows the prospect of a wide use in human medicine.
PGI combines the site specificity of CRISPR/Cas9 with enzymes capable of placing or writing DNA sequences, adding total genes, without the need for DNA double-strand breaks. Tome’s most complex generation of ERP, called integrase-mediated PGI (I-PGI), uses proprietary integrases and builds on the groundbreaking PASTE generation first discovered through Tome’s co-founders, Omar Abudayyeh, PhD, and Jonathan Gootenberg, PhD, while at MIT as researchers.
Just as a word processor pastes text anywhere in a document, I-PGI can insert giant DNA sequences anywhere in the genome with unprecedented precision. So far, I-PGI has demonstrated the insertion of more than 30 KB of site-specific genetic code into several other types of dividing and non-dividing mobiles, and can be multiplexed to create complex mobile engineering that will underpin long-term mobile treatment development. Tome has an exclusive license to the PASTE core technology, which includes U. S. Patent Nos. 11,572,556, 11,827,881 and 11,834,658.
“The ability to insert DNA sequences is a game-changer. This means that the box can now move away from random integration and use any herbal promoter in the human genome, allowing us to orchestrate tissue location, timing, and magnitude of gene expression,” said John Finn, PhD, chief scientific officer.
First, the company plans to expand integrative genetic treatments for monogenic liver diseases and mobile treatments for autoimmune diseases.
Dan Lynch, Chairman of the Board of Directors of Tome and Executive Venture Partner at GV added, “Tome has assembled a truly remarkable team to bring PGI to the many patients who could benefit from this technology. I have seen the incredible progress this team is capable of and look forward to working alongside them as we create new classes of breakthrough cell and integrative gene therapies.”
Executive Team:
Rahul Kakkar, MD, President and CEO. Rahul has more than a decade of leadership in the pharmaceutical and biotechnology industry, CEO of Pandion Therapeutics (acquired through Merck for $1. 85 billion), and founder, chief medical officer and chief strategy officer of Corvidia. Therapeutics (acquired through Novo Nordisk for $2. 1 billion).
Matt Barrows, Chief Technology Officer. Matt has over 20 years of senior leadership in CMC, including leading the manufacturing scale-up of Moderna’s COVID vaccine.
John Finn, PhD, Chief Scientific Officer. John has over 20 years of experience in gene therapy, specializing in genome editing and delivery technologies. He was an early employee of Intellia Therapeutics, where he led CRISPR/Cas9 editing for in vivo liver programs.
Edward Freedman, JD, Chief Operating Officer. Edward has more than 20 years of financial, legal and operational leadership experience, as Chief Operating Officer of Pandion Therapeutics (acquired through Merck for $1. 85 billion).
Diane Wong, Chief, People & Culture. Diane has over 15 years of HR leadership experience from both entrepreneurial and established biopharmaceutical organizations, including serving as VP of Human Resources for Constellation Pharmaceuticals (acquired by MorphoSys for $1.7B) and HR Business Partner at Novartis.
Board:
Dan Lynch, GV (President)
Jorge Condé, a16z Bio Salud
Alan Crane, Polaris
Jay Markowitz, MD, ARCH Venture Partners
Rahul Kakkar, MD, President & CEO
Omar Abudayyeh, PhD, Co-Founder, Lead Investigator at Brigham and Women’s Hospital; Jonathan Gootenberg, PhD, Co-Founder, Lead Investigator at Beth Israel Deaconess Medical Center
About TomeTome Biosciences, Inc. es a programmable genomics integration (PGI) company. Our technologies allow us to insert any genetic series of any length into any location in the genome with site-specific precision. We are writing the definitive bankruptcy of genomic medicine. providing cures to patients through integrative gene and mobile therapies. Follow us on X @Tome_Bio and on LinkedIn. www. tome. bio.
PASTE, PGI, and I-PGI™™ are technologies of Tome Biosciences, ™ Inc.
Contacts:
For Media:CG LifeCGL. TomeBio@cglife. com
For Investors: Michelle Avery, PhD, Vice President, corporatesinvestors@tome. bio Matters